Recent patient trials surrounding the medication Retatrutide , specifically the high-dose formulation referred to as ZPHC, reveal a considerable benefit on body mass reduction and linked metabolic conditions . Experts posit that this dual compound, targeting both GLP-1 and GIP receptors , may represent a substantial breakthrough in the treatment of